AR022374A1 - GUM RUBBER MEDICATION SUPPLY SYSTEM FOR NICOTINE - Google Patents
GUM RUBBER MEDICATION SUPPLY SYSTEM FOR NICOTINEInfo
- Publication number
- AR022374A1 AR022374A1 ARP990104461A ARP990104461A AR022374A1 AR 022374 A1 AR022374 A1 AR 022374A1 AR P990104461 A ARP990104461 A AR P990104461A AR P990104461 A ARP990104461 A AR P990104461A AR 022374 A1 AR022374 A1 AR 022374A1
- Authority
- AR
- Argentina
- Prior art keywords
- minutes
- nicotine
- active
- supply system
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Confectionery (AREA)
Abstract
Un sistema de suministro de goma de mascar que tiene nicotina, goma base y un sistema buffer, con un perfeccionado índice de liberacion para la nicotina.El sistema de suministro resultante proporciona convenientemente un sistema conveniente, confiable, práctico y relativamente indoloro para el suministro de unactivo. El sistema de suministro es capaz de suministrar dosis iniciales y secundarias de un activo reductor del deseo, y otros activos (por ejemplo, nicotina), cuya combinacion rápidamentereduce los deseos, o proporciona algun otro efecto farmacologico, y proporciona el efecto farmacologico o proteccion contradichos deseos durante un período de tiempo prolongado más allá de la dosis inicial. Cabe observarse que el sistema de suministro es capaz de lograr rápidamenteuna concentracion farmacologicamente efectiva del activo (por ejemplo, nicotina) en la corriente sanguínea (por ejemplo, dentro de los 5 minutos o con másconveniencia dentro de los 3 minutos, o en algunos casos, dentro de 1-2 minutos), y además es capaz de mantener la concentracion del activo en la corrientesanguínea a la concentracion farmacologicamente efectiva, o cerca de ella, durante por lo menos 20 minutos después de que comienza el mascado del sistema desuministro, o con más conveniencia, aproximadamente 30 minutos a aproximadamente 50 minutos después de que comienza el mascado.A chewing gum supply system having nicotine, gum base and a buffer system, with an improved release rate for nicotine.The resulting supply system conveniently provides a convenient, reliable, practical and relatively painless system for the supply of an active. The delivery system is capable of delivering initial and secondary doses of a desire-reducing active, and other active ingredients (for example, nicotine), the combination of which rapidly reduces desires, or provides some other pharmacological effect, and provides the pharmacological effect or contradictory protection wishes for a prolonged period of time beyond the initial dose. It should be noted that the delivery system is able to quickly achieve a pharmacologically effective concentration of the asset (for example, nicotine) in the bloodstream (for example, within 5 minutes or more conveniently within 3 minutes, or in some cases, within 1-2 minutes), and is also able to maintain the concentration of the active in the blood stream at the pharmacologically effective concentration, or near it, for at least 20 minutes after the chewing of the delivery system, or with more convenience, approximately 30 minutes to approximately 50 minutes after chewing begins.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/146,696 US6358060B2 (en) | 1998-09-03 | 1998-09-03 | Two-stage transmucosal medicine delivery system for symptom relief |
IE980991 | 1998-11-27 | ||
US36089699A | 1999-07-26 | 1999-07-26 | |
US09/389,339 US6344222B1 (en) | 1998-09-03 | 1999-09-02 | Medicated chewing gum delivery system for nicotine |
Publications (1)
Publication Number | Publication Date |
---|---|
AR022374A1 true AR022374A1 (en) | 2002-09-04 |
Family
ID=27270586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990104461A AR022374A1 (en) | 1998-09-03 | 1999-09-03 | GUM RUBBER MEDICATION SUPPLY SYSTEM FOR NICOTINE |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR022374A1 (en) |
DE (1) | DE69938347T2 (en) |
DK (1) | DK1107730T3 (en) |
MY (1) | MY124346A (en) |
-
1999
- 1999-09-03 DK DK99946722T patent/DK1107730T3/en active
- 1999-09-03 AR ARP990104461A patent/AR022374A1/en unknown
- 1999-09-03 MY MYPI99003826A patent/MY124346A/en unknown
- 1999-09-03 DE DE69938347T patent/DE69938347T2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DK1107730T3 (en) | 2008-07-14 |
MY124346A (en) | 2006-06-30 |
DE69938347T2 (en) | 2009-04-23 |
DE69938347D1 (en) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE388687T1 (en) | MEDICINAL ADMINISTRATION OF NICOTINE IN THE FORM OF CHEWING GUM | |
CR6458A (en) | VALDECOXIB COMPOSITIONS | |
CO5060522A1 (en) | ADMINISTRATION OF AN ACTIVE AGENT IN AEROSOL | |
ES2182899T3 (en) | PHARMACEUTICAL FORMULATION FOR SUBCUTANEOUS, INTRAMUSCULAR OR INTRADERMAL ADMINISTRATION OF FACTOR VIII. | |
DE3650189D1 (en) | Agents for non-systemic administration of sedatives and analgesics. | |
ATE341309T1 (en) | PULMONARY DRUG ADMINISTRATION | |
KR900701274A (en) | Dosage formulations reduce the likelihood of abuse | |
DE60044464D1 (en) | BUKKALE TRANSMUCOSAL DRUG CLEANING USING A SOLID SOLUTION | |
CY1117668T1 (en) | PHARMACEUTICAL RECOMMENDATIONS INCLUDING INSULIN CONTAINED WITH A DICETEPIPERAZINE | |
GT200000041A (en) | USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES. | |
EE03805B1 (en) | Use of an Oral Pharmaceutical Composition for the manufacture of a medicament for the treatment of erectile dysfunction in men | |
ES2159525T3 (en) | PROTECTION SYSTEM, SAFETY, FOR NEEDLE. | |
ES2171469T3 (en) | COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT. | |
DK1257254T3 (en) | Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease | |
KR900009106A (en) | Delivery system comprising means for regulating the infiltration of fluid into the system | |
BR0108730A (en) | System, device and method for administering a drug, mouthpiece of a drug delivery device, device for administering multiple unit doses of a drug, methods for preparing a drug delivery system and a drug formulation and for treatment of a patient who needs multiple doses of a drug, drug formulation and multiparticulates | |
SE9704769D0 (en) | Medical device | |
BR0115392A (en) | Method for the treatment of an interferon-sensitive disease in a warm-blooded animal, method for individualizing the dosages of an interferon in treatment, method for manufacturing a long-term therapeutic effect delivery device of a drug over a period of time, and useful set for delivering a relatively constant amount of a drug | |
TR200001891T2 (en) | ASPB28- Human insulin and its use. | |
ES2057537T3 (en) | DOSING SYSTEM WITH CONTINUOUS EMISSION. | |
AR020803A1 (en) | A COMPOSITION THAT INCLUDES FEXOFENADINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE | |
ES2114851T3 (en) | USE OF SUSTAINED RELEASE COMPOSITIONS CONTAINING GNRH, LHRH OR DERIVATIVES THEREOF. | |
ES2168241T1 (en) | PHARMACEUTICAL PREPARATION CONTAINING TOLPERISONE TO ADMINISTER BY ORAL ROUTE. | |
CO5200840A1 (en) | COMBINATION OF ACTIVE SUBSTANCES WITH CLONIDINE | |
PT904067E (en) | DEXTROMETORFAN AS AN ANTISUSTIC AGENT TRANSMEDICALLY ADMINISTERED |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |